Liminatus Pharma (LIMN) Advances CD47 Immunotherapy with Enhanced Safety Profile and Korean Clinical Collaboration
Liminatus Pharma, Inc (NASDAQ:LIMN) LA PALMA, CA, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Liminatus is advancing a second-generation CD47 antibody, IBA101, intended to improve the safety and performance profile of macrophage-based …